Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casirivimab+Imdevimab in healthy volunteers
NCT05181683Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of casirivimab + imdevimab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Targeted grade ≥3 treatment-emergent adverse events at 16 weeks, Grade ≥3 injection-site reactions at 16 weeks and 3 more. Started Jan 2022; status: completed.
02
Drugs
casirivimab + imdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05181683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181683.